论文部分内容阅读
目的探讨25-羟维生素D水平与肾癌发病的关系。方法选取2015年3月至2017年8月安徽医科大学第二附属医院收治的初治肾癌患者100例设为肾癌组,同期选择本院体检者采用倾向性评分法匹配200例非肿瘤人群为对照组,检测两组人群25-羟维生素D水平,比较两组患者的一般临床资料、实验室检查(如血钠、血磷、血钙及血肌酐)及25-羟维生素D水平等资料。采用单因素分析与因变量相关的变量,将有统计学意义的变量纳入多因素二分类logistic回归中再次分析。结果 25-羟维生素D(B=-0.067,OR=0.935,P=0.001)及高血压(B=0.064,OR=1.896,P=0.001)是影响肾癌发病的独立危险因素。结论高水平的25-羟维生素D是肾癌的保护因素。
Objective To investigate the relationship between the level of 25-hydroxyvitamin D and the incidence of renal cell carcinoma. Methods From March 2015 to August 2017, 100 patients with newly diagnosed renal cell carcinoma admitted to the Second Affiliated Hospital of Anhui Medical University were enrolled as the renal cell carcinoma group. In the same period, the physical score of the selected patients in our hospital was matched with 200 non-tumor patients As the control group, the level of 25-hydroxyvitamin D in the two groups was tested. The general clinical data, laboratory tests (such as serum sodium, serum phosphorus, serum calcium and serum creatinine) and 25-hydroxyvitamin D . Univariate analysis was used to analyze the variables associated with the dependent variables, and statistically significant variables were included in the multivariate logistic regression of the binary classification. Results 25-hydroxyvitamin D (B = -0.067, OR = 0.935, P = 0.001) and hypertension (B = 0.064, OR = 1.896, P = 0.001) were independent risk factors for the pathogenesis of renal cell carcinoma. Conclusion High levels of 25-hydroxyvitamin D are protective factors for renal cancer.